Speeded Anomia Treatment in Chronic Post-stroke Aphasia

January 16, 2023 updated by: Matthew A. Lambon Ralph, University of Cambridge

Testing the Effect of Speeded Anomia Therapy in Patients With Chronic Post-stroke Aphasia: a Cross-over Randomized Controlled Trial

The main aim of the study is to investigate the effect of a novel, speeded anomia therapy (Conroy et al., 2018) in a large population of patients with chronic post-stroke aphasia. The treatment will be delivered via a web application (QuickWord).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The main aim is to test the clinical efficacy of a novel, web based, rehabilitation approach to aphasic word-finding difficulties (QuickWord). In an initial development and case-series evaluation, Conroy et al (2018, Brain) found that training for both speed as well as accuracy of naming generated much better outcomes to picture naming accuracy and also augmented the carry-over to connected speech production.

This is a randomised, crossover, clinical trial of QuickWord in a group of aphasic patients in the chronic post-stroke period. The comparison will be standard care. The main outcome measures are clinically relevant improvement in naming to confrontation, and spontaneous use of the target vocabulary in a connected speech sample (detailed picture description). Secondary outcome includes measured use of the vocabulary in a story-telling, connected speech assessment (retelling of the Cinderella story).

Study Type

Interventional

Enrollment (Anticipated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Native English speakers
  • Age 18 years or above
  • Stroke (any type) greater than 12 months post onset
  • No history of neurological disorders / psychiatric disorders
  • Normal or corrected-to-normal hearing & vision
  • Able to give informed consent
  • Currently not receiving Speech & Language therapy
  • Minimal repetition skills (>40% on an immediate word repetition test)
  • Evidence of naming difficulties (<90% in Boston Naming Test - Goodglass et al., 1983)

Exclusion Criteria:

  • Non-native English speakers
  • Less than 18 years old
  • Stroke less than 12 months post onset
  • History of neurological disorders / psychiatric disorders
  • Uncorrected hearing & vision
  • Unable to give informed consent
  • Currently receiving Speech & Language therapy
  • Insufficient repetition skills (<40% on an immediate word repetition test)
  • Good naming performance (>90% in Boston Naming Test - Goodglass et al., 1983)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Speeded anomia therapy
21h of anomia therapy
Behavioral: Speeded anomia therapy
The speeded anomia therapy was introduced as RISP (Repeated, Increasingly Speeded Production) by Conroy et al. (2018). Participants are asked to name the picture presented to them before an auditory stimulus ('beep' sound) at the end of item presentation. In each session the allotted response time is gradually reduced. After an incorrect response, participants are asked to repeat the word three times.
No Intervention: Standard care
Participants' typical daily routine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Speeded anomia therapy effect in reaction time
Time Frame: Measured over 10 weeks (Week 0, Week 2, Week 4, Week 6, Week 10)
Change in reaction time in single-item picture naming
Measured over 10 weeks (Week 0, Week 2, Week 4, Week 6, Week 10)
Speeded anomia therapy effect in accuracy
Time Frame: Measured over 10 weeks (Week 0, Week 2, Week 4, Week 6, Week 10)
Change in accuracy in single-item picture naming
Measured over 10 weeks (Week 0, Week 2, Week 4, Week 6, Week 10)
Generalisation to connected speech
Time Frame: Measured over 10 weeks (Week 0, Week 2, Week 4, Week 6, Week 10)
Change in word retrieval in composite picture description. Participants will be asked to describe composite pictures (from the "Where's Waldo/Wally?" publications).
Measured over 10 weeks (Week 0, Week 2, Week 4, Week 6, Week 10)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Generalisation to story-telling connected speech
Time Frame: Measured over 10 weeks (Week 0, Week 2, Week 4, Week 6, Week 10)
Change in narrative speech production. Participants will be asked to narrate the Cinderella story. A checklist with some of the most frequently used nouns (data obtained from AphasiaBank database) will be used.
Measured over 10 weeks (Week 0, Week 2, Week 4, Week 6, Week 10)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Cambridge

Collaborators

Cambridge University Hospitals NHS Foundation Trust

Investigators

  • Principal Investigator: Matthew Lambon Ralph, DPhil, MRC Cognition and Brain Sciences Unit, University of Cambridge

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

January 15, 2023

Primary Completion (Anticipated)

September 1, 2023

Study Completion (Anticipated)

September 1, 2023

Study Registration Dates

First Submitted

August 17, 2022

First Submitted That Met QC Criteria

August 20, 2022

First Posted (Actual)

August 23, 2022

Study Record Updates

Last Update Posted (Actual)

January 19, 2023

Last Update Submitted That Met QC Criteria

January 16, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 01/8/094

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aphasia

Clinical Trials on Speeded anomia therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe